Schaefer, Gabriele

Oncogenic ERBB3 mutations in human cancers.

Jaiswal, B. S., Kljavin, N. M., Stawiski, E. W., Chan, E., Parikh, C., Durinck, S., Chaudhuri, S., Pujara, K., Guillory, J., Edgar, K. A., et al. (2013) · Cancer Cell

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 350

The Intrinsic Contributions of Tyrosine, Serine, Glycine and Arginine to the Affinity and Specificity of Antibodies

Birtalan, S., Zhang, Y., Fellouse, F. A., Shao, L., Schaefer, G., & Sidhu, S. S. (2008) · Journal of Molecular Biology

Monoclonal and Polyclonal Antibodies ResearchChemical Synthesis and Analysis

Cited by 244

Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M

Lee, H.-J., Schaefer, G., Heffron, T. P., Shao, L., Ye, X., Sideris, S., Malek, S., Chan, E., Merchant, M., La, H., et al. (2013) · Cancer Discovery

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 90

Clinical responses to ERK inhibition in BRAF V600E-mutant colorectal cancer predicted using a computational model

Kirouac, D. C., Schaefer, G., Chan, J., Merchant, M., Orr, C., Huang, S.-M. A., Moffat, J., Liu, L., Gadkar, K., & Ramanujan, S. (2017) · npj Systems Biology and Applications

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 60

Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose

Kamath, A. V., Lu, D., Gupta, P., Jin, D., Xiang, H., Wong, A., Leddy, C., Crocker, L., Schaefer, G., Sliwkowski, M. X., et al. (2012) · Cancer Chemotherapy and Pharmacology

Monoclonal and Polyclonal Antibodies ResearchHER2/EGFR in Cancer Research

Cited by 41